Overview

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19

Status:
Not yet recruiting

Trial end date:
2023-07-30

Target enrollment:

Participant gender:

Summary

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Ritonavir